Boston Scientific Announces Results for Second Quarter 2024
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall Street rallies as Fed's Waller eases rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
Boston Scientific (BSX) PT Raised to $78 at Deutsche Bank
July 25, 2024 5:07 AM EDTDeutsche Bank analyst Pito Chickering raised the price target on Boston Scientific (NYSE: BSX) to $78.00 (from $73.00) while maintaining a Hold rating.
The analyst comments "All told, Boston continues to execute at a high level, with continued portfolio shift to higher-growth segments (WAMGR has increased to HSD from LSD historically), leaving the... More
Boston Scientific (BSX) PT Raised to $90 at Jefferies
July 24, 2024 1:39 PM EDTJefferies analyst Matthew Taylor raised the price target on Boston Scientific (NYSE: BSX) to $90.00 (from $82.00) while maintaining a Buy rating.
The analyst comments "BSX reported 2Q24 sales of $4.12B, +14.7% organic, vs cons $4.02B and EPS of $0.62 +17%. vs cons $0.58. BSX increased '24 guidance to... More
BTIG Reiterates Buy Rating on Boston Scientific (BSX)
July 24, 2024 12:30 PM EDTBTIG analyst Marie Thibault reiterated a Buy rating and $84.00 price target on Boston Scientific (NYSE: BSX).
The analyst comments "This was another impressive quarter from Boston Scientific. Yet with the stock seemingly priced for perfection, shares traded off on Wednesday morning as a beat was widely anticipated and investors focused on whether the strong growth can be sustained beyond the Farapulse launch. BSX reported Q2 revenue of $4.120B (+14.5% y/y rep., +14.7% y/y org.) and adj. EPS of $0.62 (consensus $4.021B and $0.58), besting its guidance of +10.5-12.5% y/y reported sales growth,... More
Boston Scientific (BSX) PT Raised to $82 at Evercore ISI
July 24, 2024 12:04 PM EDTEvercore ISI analyst Vijay Kumar raised the price target on Boston Scientific (NYSE: BSX) to $82.00 (from $81.00) while maintaining a Outperform rating.
The analyst comments "Thesis Update: BSX reported an overall organic growth of ~14.7% and EPS growth of ~16%...while these are numbers that any company can be proud of, BSX shares are down -3% as we write this. We would notch the share reaction to the expectations game, which seems a little odd to us given that consensus trades have worked so far (ISRG up DD on hitting buyside expecs for systems).... More
Citi Reiterates Buy Rating on Boston Scientific (BSX), Top Pick
July 24, 2024 7:37 AM EDTCiti analyst Joanna Wuensch reiterated a Buy rating and $90.00 price target on Boston Scientific (NYSE: BSX).
The analyst comments "BSX delivered a strong 2Q24 results ahead of expectations with revenue of $4.12B (up 14.7% organic, ahead of consensuss $4.02B). The beat was broad based,... More
